{"id":521198,"date":"2021-08-02T08:04:45","date_gmt":"2021-08-02T12:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/"},"modified":"2021-08-02T08:04:45","modified_gmt":"2021-08-02T12:04:45","slug":"cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/","title":{"rendered":"CytomX Therapeutics to Present at Upcoming August Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Aug.  02, 2021  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody\u00ae technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August.<\/p>\n<p>\n        <strong>BTIG 5th Virtual Biotechnology Conference<\/strong><br \/>\n        <br \/>Date: Monday, August 9, 2021 <br \/>Presentation Time: 1:00 p.m. ET.<\/p>\n<p>\n        <strong>2021 Wedbush PacGrow Healthcare Virtual Conference<\/strong><br \/>\n        <br \/>Date: Tuesday, August 10, 2021<br \/>Panel Discussion: 1:10 p.m. ET<\/p>\n<p align=\"justify\">In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CytomX Therapeutics<\/strong><br \/>\n        <br \/>CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody\u00ae technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.<\/p>\n<p align=\"justify\">Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies. First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probodies, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). For additional information about CytomX Therapeutics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dtbULAU1qJxtKNam2n24HaCM3ShxriQ8bTP0hRbQKhwBODls1sKByy9rD55uhDhns5GmiCMQjxnOWDSD6iO7YQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.cytomx.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A2anwLjEYi35CsSO-QhXezPdF0DT5qOLZQsL6tgIp4bU68b0niPKpccJpZLbbwK8srkXMpxQbDXs7rl7_lcJA2R39b5D3tNSJXNlJ1yw-Xi9Uw6mmE8PoqpCBj-KvELo\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lza8tr1391awEvJFKZP1D40sWTNjyCWRSPgKFVTHFylZ5p1PeDJb2bMWcCIsMYC8N_GAIG1XBXFtBCqMsyPMkewuvhbqvXSYLp_Fjh3G0IY=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p align=\"justify\">Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Chau Cheng, PhD MBA<br \/>VP, Investor Relations &amp; Corp. Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=58yPDqZmVCxXhq_bbGjUrNokcDD8p1CVtyxhnG9lo3Zl-FNxG8o4STFRehGtNGYqdPf5ckRbydo_DX0_gsTM_A==\" rel=\"nofollow noopener\" target=\"_blank\">ccheng@cytomx.com<\/a><br \/>Direct: (650) 273-4999<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Bret Coons<br \/>Director, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IGb5B0Xc8yiLh6zusmzm1j-1SPGsUbsxTuyaVUKj3yzXQPy_q7x0iv2XtxCw_V7Gt7kxA7UrZmIZNoB5dqCytQ==\" rel=\"nofollow noopener\" target=\"_blank\">bcoons@cytomx.com<\/a><br \/>Direct: (650) 528 2929\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/67fe8112-8f89-4e64-9130-fa26d9f66251\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody\u00ae technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August. BTIG 5th Virtual Biotechnology Conference Date: Monday, August 9, 2021 Presentation Time: 1:00 p.m. ET. 2021 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10, 2021Panel Discussion: 1:10 p.m. ET In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Present at Upcoming August Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521198","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody\u00ae technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August. BTIG 5th Virtual Biotechnology Conference Date: Monday, August 9, 2021 Presentation Time: 1:00 p.m. ET. 2021 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10, 2021Panel Discussion: 1:10 p.m. ET In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming &hellip; Continue reading &quot;CytomX Therapeutics to Present at Upcoming August Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T12:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Present at Upcoming August Investor Conferences\",\"datePublished\":\"2021-08-02T12:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/\"},\"wordCount\":441,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/\",\"name\":\"CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\",\"datePublished\":\"2021-08-02T12:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Present at Upcoming August Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody\u00ae technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August. BTIG 5th Virtual Biotechnology Conference Date: Monday, August 9, 2021 Presentation Time: 1:00 p.m. ET. 2021 Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10, 2021Panel Discussion: 1:10 p.m. ET In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming &hellip; Continue reading \"CytomX Therapeutics to Present at Upcoming August Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T12:04:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Present at Upcoming August Investor Conferences","datePublished":"2021-08-02T12:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/"},"wordCount":441,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/","name":"CytomX Therapeutics to Present at Upcoming August Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=","datePublished":"2021-08-02T12:04:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDM5NSM0MzA4MDI3IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Present at Upcoming August Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521198"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521198\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}